EyePoint (EYPT) vs Standard BioTools (LAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Standard BioTools (LAB) has outperformed EyePoint (EYPT) over the past year, losing 54.3% versus a loss of 98.3%. Over five years, LAB leads with a -86.5% price change compared with -98.6% for EYPT. Standard BioTools is the larger company by market cap ($249.1 million vs $26.6 million), about 9.3 times the size.
Standard BioTools converts more of its revenue into profit, with a net margin of -87.8% versus -739.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EYPT | LAB |
|---|---|---|
| Share price | $0.2342 | $0.631 |
| Market cap | $26.65M | $249.11M |
| 1-day change | -11.36% | +2.82% |
| YTD return | -98.72% | -50.70% |
| 1-year return | -98.29% | -54.28% |
| 5-year return | -98.58% | -86.55% |
| EPS (TTM) | $-3.97 | $-0.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $31.37M | $85.33M |
| Revenue growth (YoY) | -27.50% | -6.24% |
| Net income (latest FY) | $-231.96M | $-74.90M |
| Gross margin | — | 49.86% |
| Operating margin | -775.98% | -129.20% |
| Net margin | -739.42% | -87.77% |
| 52-week high | $19.11 | $1.72 |
| 52-week low | $0.2277 | $0.39 |
| Distance from 52-week high | -98.77% | -63.31% |
| Analyst consensus | buy | none |
| Avg. price target upside | +10963.19% | +113.95% |
| Average volume | 8.37M | 1.16M |
| Shares outstanding | 113.78M | 394.79M |
| Employees | 214 | 385 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Standard BioTools is about 9.3 times larger than EyePoint by market value ($249.11M vs $26.65M).
- LAB has outperformed EYPT by 44.0 percentage points over the past year.
- Standard BioTools is more profitable, keeping -87.8 cents of every revenue dollar as net income versus -739.4 cents for EyePoint.
- Standard BioTools grew revenue faster in its latest fiscal year (-6.24% vs -27.50%).
About EyePoint
EYPT stock →EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
Industrials · Biotechnology: Laboratory Analytical Instruments · 214 employees
About Standard BioTools
LAB stock →Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments.
Industrials · Biotechnology: Laboratory Analytical Instruments · 385 employees
EYPT vs LAB FAQ
Which is bigger, EyePoint or Standard BioTools?
Standard BioTools (LAB) is larger, with a market capitalization of $249.11M compared with $26.65M for EyePoint (EYPT).
Which stock has performed better over the past year, EYPT or LAB?
LAB returned -54.28% over the past 12 months, compared with -98.29% for EYPT (price return, excluding dividends). Past performance does not predict future results.
Are EyePoint and Standard BioTools in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.